BuySellShort's  Instablog

Send Message
Chief Market Strategist at Learn how to make a living trading small and midcap stocks. Additional Disclaimer: I may buy and sell any positions mentioned in any article at any time.
My company:
My blog:
My book:
Trading Biotech Stocks
  • Does Biogen Idec have a Buyout Offer on the Table? 2 comments
    Jul 21, 2009 11:15 AM | about stocks: BIIB, ELN, JNJ

    For the last year rumors of buyouts have been floated around on Biogen Idec, no surprise really given the constant pressure from corporate raider Carl Ichan.  Those rumors are likely pick up steam yet again after the earnings report from BIIB’s Tysabri partner ELN today.

    Tysabri, the multiple sclerosis drug shared 50/50 with Ireland’s Elan Corp has been a torn in the side of Biogen for the last few years with infrequent reports of PML hammering the stock every few weeks. Tysabri is only the second drug ever pulled from the market by the FDA that was allowed back to market.  The stock soared last year on an expected buyout that eventually turned soar after cases of PML were reported.


    Under the Tysabri agreement ELN has with BIIB should BIIB undergo a change of control (ie. merger or buyout) then ELN has the right to purchase BIIB’s 50% stake in Tysabri. In today’s Elan conference call ELN’s management team mentioned that Biogen Idec has approached them and offered $700m to purchase ELN’s right to the change of control clause. This large price tag for just the clause rights could suggest BIIB is about to merge or be bought and with Tysabri considered a lynchpin of any deal BIIB may be trying to tie up a potential deal breaker. Interestingly enough ELN mentioned that should there be a change of control at BIIB that JNJ has agreed to finance ELN’s purchase of Tysabri. The plot thickens. If news that BIIB has paid ELN surfaces you can bet a buyout of BIIB is just around the corner.

    Disclosure: Long ELN
    Stocks: BIIB, ELN, JNJ
Back To BuySellShort's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • mark432
    , contributor
    Comment (1) | Send Message
    Tysabri was not pulled from the market. Biogen Idec chose to pull it themselves. Please check your facts.
    21 Jul 2009, 01:11 PM Reply Like
  • Furd Turgeson
    , contributor
    Comments (28) | Send Message
    The only company now with any reason whatsoever to buy Biogen is JNJ. I bet they don't any time soon.
    21 Jul 2009, 07:04 PM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.